



PERIMETER

Imaging Like You've Never Seen Before

Weekly IR Round-Up

Defining our "Why"

The physical, emotional, and financial costs are staggeringly high when a patient is faced with a re-excision procedure. A [recent study](#) published by researchers at MD Anderson Cancer Center quantifies some of these impacts.

Did you know that **40% of patients with DCIS** (an early form of breast cancer) have reoperations due to positive margins?

10% to 36% of those patients will convert to mastectomy, greatly increasing complication risks and healthcare costs.

Increase in Cost and Risk with Conversion to Mastectomy in DCIS Patients



96%

increase in costs to the
healthcare system



80%

increase in
complication risk

What are Reoperations in Breast Surgery Costing Healthcare Systems?



24%

Increase in
healthcare costs



Ages 18-64


+\$21,607

Ages 65+

+\$8,559

Cost increase for reoperations per age group

Overall reoperation rates for breast-conserving surgery were 21% in females between 18–64 years old and 15% in females 65 years and older. Compared to women with invasive breast cancer (IBC), DCIS patients had even higher reoperation rates: 18% vs. 31% (age 18- 64) and 13% vs. 24% (age 65+). Women aged 18-44 with DCIS and commercial insurance had the highest reoperation rate at 40%.



These reoperation realities, on top of the rising incidence of breast cancer in younger women, are the reasons why Perimeter is working diligently on developing innovative technology solutions. We are helping our surgeon customers gain better clarity on margin status in the OR - providing actionable, real-time insights to tailor clinical decisions to each patient - as they strive to reduce re-excisions.

Let's Stay Connected

Follow Perimeter Medical on Social!

The best way to hear the latest news from Perimeter is to follow us on one of our social media channels:

- **X** (formerly Twitter): <https://twitter.com/PerimeterMed>
- **LinkedIn**: <https://www.linkedin.com/company/perimeter-medical-imaging/>

You can also sign up to get Perimeter [news release alerts](#) delivered directly to your email or check out the news feed on our [investor website](#).

Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit www.perimetermed.com/disclosures.

For more information about Perimeter, please contact: investors@perimetermed.com

*You are receiving this email because you signed up for news alerts from Perimeter Medical Imaging AI. Please use the **"Unsubscribe Preferences"** link below if you wish*

to opt out of this e-newsletter.



Perimeter Medical Imaging AI, 8585 N. Stemmons Freeway, Suite 106N, Dallas, TX 75247

[Unsubscribe Preferences](#)

[TSXV: PINK](#) | [OTC PYNKF](#) | [FSE: 4PC](#)



© 2024 Perimeter Medical Imaging AI, Inc.